Merck Insomnia Drug Shows Improvements; Filing On Track
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck is confident it can compete in the highly generic insomnia market; Phase III results show the insomnia drug suvorexant may have further benefits for patients.